Agree, that statement appear under "Company Overview". The 3 IP with IND FDA are replacing SoC unlike the B Cell Platform so are more valuable assets. IMU already has access to manufacturing plant through the acquisition for Azer-Cel so the manufacturing of these drugs for the clinical trial can be produced there.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.2¢ |
Change
-0.001(7.69%) |
Mkt cap ! $93.33M | |||
| Open | High | Low | Value | Volume |
| 1.2¢ | 1.3¢ | 1.2¢ | $85.91K | 7.041M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 59 | 13853497 | 1.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.3¢ | 12115001 | 36 |
View Market Depth
| Last trade - 14.13pm 24/06/2025 (20 minute delay) ? |
| IMU (ASX) Chart |